Helius Medical Technologies is a neurotechnology company. Co. develops, licenses or acquires non-implanted technologies targeted at reducing symptoms of neurological disease or trauma. Co.'s primary product, known as the Portable Neuromodulation Stimulator, is authorized for sale in Canada for two indications: for use as a short term treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy; and for use as a short term treatment of gait deficit due to mild and moderate symptoms from multiple sclerosis and it is to be used in conjunction with physical therapy. The HSDT average annual return since 2014 is shown above.
The Average Annual Return on the HSDT average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether HSDT average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the HSDT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free HSDT Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
